Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Satellos Bioscience ( (TSE:MSCL) ) has shared an update.
Satellos Bioscience Inc. has completed the enrollment of all four multiple-ascending dose cohorts for the Phase 1 clinical trial of its oral small molecule drug, SAT-3247, in healthy volunteers. This milestone is part of the company’s mission to deliver transformative therapies for degenerative diseases, specifically Duchenne muscular dystrophy (DMD), marking progress toward presenting Phase 1 data in 2025 and advancing the treatment as a potential novel therapy for muscle regeneration.
More about Satellos Bioscience
Satellos Bioscience Inc. is a public biotech company focused on developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders.
YTD Price Performance: -14.42%
Average Trading Volume: 123,351
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $84.44M
For a thorough assessment of MSCL stock, go to TipRanks’ Stock Analysis page.
